Jaap Goudsmit

Summary

Affiliation: Crucell Holland BV
Country: The Netherlands

Publications

  1. ncbi request reprint A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis
    John de Kruif
    Crucell Holland BV, Leiden, The Netherlands
    Annu Rev Med 58:359-68. 2007
  2. pmc Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma
    Antoinette C van der Kuyl
    Department of Human Retrovirology, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    BMC Cancer 2:21. 2002
  3. pmc Gene expression profile of AIDS-related Kaposi's sarcoma
    Marion Cornelissen
    Department of Human Retrovirology, Academic Medical Centre, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    BMC Cancer 3:7. 2003
  4. ncbi request reprint Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin
    Jaap Goudsmit
    Crucell Holland BV, Leiden, The Netherlands
    J Infect Dis 193:796-801. 2006
  5. ncbi request reprint Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
    Olga J A E Ophorst
    Crucell Holland BV, P O Box 2048, 2301 CA Leiden, The Netherlands
    Vaccine 25:6501-10. 2007
  6. ncbi request reprint High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector
    Ronald Vogels
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Gen Virol 88:2915-24. 2007
  7. pmc Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1
    Ariane Rodriguez
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 76:1709-18. 2008
  8. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
  9. ncbi request reprint Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity
    Angelique A C Lemckert
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Gen Virol 87:2891-9. 2006
  10. doi request reprint Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys
    Ariane Rodriguez
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    Vaccine 27:6226-33. 2009

Research Grants

  1. CORE--VECTOR
    Jaap Goudsmit; Fiscal Year: 2005

Detail Information

Publications77

  1. ncbi request reprint A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis
    John de Kruif
    Crucell Holland BV, Leiden, The Netherlands
    Annu Rev Med 58:359-68. 2007
    ..Using this process as a model, the general requirements for development of safe and efficacious monoclonal antibody alternatives to currently used polyclonal serum products are discussed...
  2. pmc Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma
    Antoinette C van der Kuyl
    Department of Human Retrovirology, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    BMC Cancer 2:21. 2002
    ..From in vitro studies it has become clear that these drugs can affect specific genes, as well as have an effect upon the total transcriptome...
  3. pmc Gene expression profile of AIDS-related Kaposi's sarcoma
    Marion Cornelissen
    Department of Human Retrovirology, Academic Medical Centre, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    BMC Cancer 3:7. 2003
    ..Its course is aggravated by co-infection with HIV-1, where the timing of infection with HIV-1 and HHV8 is important for the clinical outcome...
  4. ncbi request reprint Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin
    Jaap Goudsmit
    Crucell Holland BV, Leiden, The Netherlands
    J Infect Dis 193:796-801. 2006
    ..These results demonstrate that the human MAb cocktail of CR57 and CR4098 is a safe and efficacious alternative to RIG in rabies postexposure prophylaxis...
  5. ncbi request reprint Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
    Olga J A E Ophorst
    Crucell Holland BV, P O Box 2048, 2301 CA Leiden, The Netherlands
    Vaccine 25:6501-10. 2007
    ..CS alone. With these results we report for the first time the feasibility of using an AlPO(4) adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine...
  6. ncbi request reprint High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector
    Ronald Vogels
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Gen Virol 88:2915-24. 2007
    ..Such rAd35 vectors thus expand the utility of rAd35 vaccine carriers for the development of vaccines against, for example, malaria, AIDS and tuberculosis...
  7. pmc Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1
    Ariane Rodriguez
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 76:1709-18. 2008
    ..Our results show the ability of rAd35 to induce potent T-cell immunity in combination with protein in a prime-boost schedule without impairing the B-cell response...
  8. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  9. ncbi request reprint Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity
    Angelique A C Lemckert
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Gen Virol 87:2891-9. 2006
    ..SIVGag vaccine. These data demonstrate the potential of a replication deficient human group D adenoviral vector for vaccination purposes...
  10. doi request reprint Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys
    Ariane Rodriguez
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    Vaccine 27:6226-33. 2009
    ..CS or possibly another adenovector of a distinct serotype, induces a complex immune response that is required for protection against malaria, and is thus a highly promising approach for pediatric vaccination...
  11. doi request reprint Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants
    Katarina Radosevic
    Crucell Holland BV, Leiden, The Netherlands
    Vaccine 26:3640-6. 2008
    ....
  12. pmc Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus
    Mark Throsby
    Crucell Holland B V, P O Box 2048, 2301 CA, Leiden, The Netherlands
    J Virol 80:6982-92. 2006
    ....
  13. ncbi request reprint The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
    R Arjen Kramer
    Crucell Holland B V, Leiden, The Netherlands
    Eur J Immunol 35:2131-45. 2005
    ..The obtained specificities expand the set of human anti-RV antibodies eligible for inclusion in an antibody cocktail aimed for use in rabies post-exposure prophylaxis...
  14. pmc Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus
    Edward N van den Brink
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Virol 79:1635-44. 2005
    ..The complete set of SARS-CoV MAbs described here may be useful for diagnosis, chemoprophylaxis, and therapy of SARS-CoV infection and disease...
  15. pmc Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells
    Mark Throsby
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 3:e3942. 2008
    ..Furthermore, there are 16 different HA subtypes and no certainty the next pandemic will be caused by an H5 subtype, thus it is important to develop prophylactic and therapeutic interventions that provide heterosubtypic protection...
  16. ncbi request reprint Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development
    Mark Throsby
    Crucell Holland BV, Leiden, The Netherlands
    Expert Rev Vaccines 6:183-91. 2007
    ..This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines...
  17. pmc Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis
    Wilfred E Marissen
    Crucell Holland BV, Archimedesweg 4, P O Box 20482301, CA Leiden, The Netherlands
    J Virol 79:4672-8. 2005
    ....
  18. pmc Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5
    Lennart Holterman
    Crucell Holland BV, Leiden, The Netherlands
    J Virol 78:13207-15. 2004
    ..We therefore conclude that the Ad11-based vector represents a novel and useful candidate gene transfer vehicle for vaccination and gene therapy...
  19. pmc Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples
    Stefan Kostense
    Crucell Holland BV, Leiden, The Netherlands
    Antimicrob Agents Chemother 56:3524-30. 2012
    ..We concluded that the assay is suitable for the measurement of polyclonal and monoclonal rabies neutralizing antibodies in clinical serum samples...
  20. doi request reprint Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir
    Wouter Koudstaal
    Crucell Holland BV, 2333 CN Leiden, The Netherlands
    J Infect Dis 200:1870-3. 2009
    ..These results justify further preclinical evaluation of broadly neutralizing mAbs against influenza virus for the prevention and treatment of influenza virus infections...
  21. pmc Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity
    Angelique A C Lemckert
    Crucell Holland B V, Leiden, The Netherlands
    J Virol 79:9694-701. 2005
    ..Nevertheless, these data suggest the potential utility of heterologous rAd prime-boost vaccine regimens using vectors derived from rare human Ad serotypes...
  22. doi request reprint Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects
    Katarina Radosevic
    Immunology and Proof of Concept, Innovation and Discovery Lab, Crucell Holland BV, Leiden, The Netherlands
    Expert Rev Vaccines 8:577-92. 2009
    ..This review provides an overview of heterologous prime-boost vaccination modalities currently in development for the 'big three' poverty-related diseases and emphasizes the need for innovative vaccination approaches...
  23. ncbi request reprint Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence
    Olga J A E Ophorst
    Crucell Holland BV, P O Box 2048, Leiden 2301 CA, The Netherlands
    Vaccine 25:1426-36. 2007
    ..Our results show that rational design of antigens is warranted for further development of malaria vaccines...
  24. ncbi request reprint An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity
    Olga J A E Ophorst
    Crucell Holland BV, P O Box 2048, Leiden 2301 CA, The Netherlands
    Vaccine 22:3035-44. 2004
    ..We thus conclude that, for ex vivo vaccination, Ad5.Fib35 shows promise as vector for loading of DC but is unable to circumvent anti-Ad5 immunity limiting its in vivo utility...
  25. pmc Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species
    Roland Zahn
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 7:e44115. 2012
    ..Combination of the five selected filovirus glycoproteins in one multivalent vaccine potentially elicits protective immunity in man against all major filovirus strains that have caused lethal outbreaks in the last 20 years...
  26. ncbi request reprint Quantification of residual host cell DNA in adenoviral vectors produced on PER.C6 cells
    Linda Gijsbers
    Crucell Holland BV, 2301CA Leiden, The Netherlands
    Hum Gene Ther 16:393-8. 2005
    ..C6 cells throughout a standard purification process. Because of its specifications, we anticipate that the assay can have broad applicability to biologics other than adenoviral vectors produced on PER.C6 cells...
  27. ncbi request reprint Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors
    Sandra Verhaagh
    Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
    J Gen Virol 87:255-65. 2006
    ..SIVgag vaccine as compared with rAd35.SIVgag exposed dendritic cells from wild-type littermates. It was concluded that MYII mice represent an interesting preclinical model to evaluate potency and safety of rAd35 vectors...
  28. pmc Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
    Ronald Vogels
    Vaccine R and D Division, Crucell Holland BV, 2301CA Leiden, The Netherlands
    J Virol 77:8263-71. 2003
    ..We further demonstrate that transduction with Ad35 is not hampered by preexisting Ad5 immunity and that Ad35 efficiently infects dendritic cells, smooth muscle cells, and synoviocytes, in contrast to Ad5...
  29. pmc New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets
    Robert H E Friesen
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 5:e9106. 2010
    ..Here we report the latest efficacy data for a representative antibody of this novel class...
  30. ncbi request reprint Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
    Stefan Kostense
    Crucell Holland BV, Leiden, The Netherlands
    AIDS 18:1213-6. 2004
    ..Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV...
  31. pmc The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert
    Katarina Radosevic
    Crucell Holland B V, Archimedesweg 4 6, 2333 CN Leiden, Netherlands
    Clin Vaccine Immunol 17:1687-94. 2010
    ..CS/Ad26.CS vaccine at a later age, to induce lasting protection against malaria for which the Th1 response and immune memory is required...
  32. ncbi request reprint Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method
    Johan C Kapteyn
    Crucell Holland BV, P O Box 2048, 2301 CA Leiden, The Netherlands
    Vaccine 24:3137-44. 2006
    ..C6((R)) cell cultures. The RP-HPLC assay selectivity allows for the simultaneous identification and quantification of HA(1) from influenza A and B strains in the yearly revised trivalent vaccines for epidemic outbreaks...
  33. ncbi request reprint Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 41:232-7. 2006
    ..Plasma viral load testing can ensure a more efficient allocation of antiretroviral therapy but only when applied to a strategy of active case finding in the community...
  34. pmc Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
    Jan Ter Meulen
    Crucell Holland B V, Leiden, Netherlands
    PLoS Med 3:e237. 2006
    ..Combinations of virus-neutralizing, noncompeting mAbs may have these properties...
  35. pmc A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines
    Stefan Kostense
    Crucell Holland, CA Leiden, The Netherlands
    Clin Vaccine Immunol 18:776-82. 2011
    ..Antibody titers were in agreement with total antibody responses to the whole CS protein. Due to its simplicity and high performance, the ELISA is an easy and rapid method for assessment of pre-erythrocyte malaria vaccines based on CS...
  36. doi request reprint A common solution to group 2 influenza virus neutralization
    Robert H E Friesen
    Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, 2333 CN, Leiden, The Netherlands
    Proc Natl Acad Sci U S A 111:445-50. 2014
    ..The identification of another antibody against the group 2 stem epitope suggests that this conserved site of vulnerability has great potential for design of therapeutics and vaccines. ..
  37. ncbi request reprint The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis
    Johannes Antonie Bogaards
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    Travel Med Infect Dis 5:70-8. 2007
    ..If new mutants of SARS coronavirus do initiate another epidemic, administration of prophylactic antibodies to risk groups may supplement the stringent isolation procedures that contained the first SARS outbreak...
  38. ncbi request reprint Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber
    Elisabeth H Slager
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Gene Ther 11:227-36. 2004
    ....
  39. pmc Mechanisms of hemagglutinin targeted influenza virus neutralization
    Boerries Brandenburg
    Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Leiden, The Netherlands
    PLoS ONE 8:e80034. 2013
    ..These insights into newly identified ways by which the human immune system can interfere with influenza virus infection may aid the development of novel universal vaccines and antivirals. ..
  40. doi request reprint PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine
    Barbara P Sanders
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Vaccine 31:850-6. 2013
    ..Based on our findings, we are exploring PER.C6(®) as an interesting platform for large-scale production of poliovirus at low costs, potentially providing the basis for global supply of an affordable IPV...
  41. ncbi request reprint Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
    Jan Ter Meulen
    Crucell Holland BV, Leiden, Netherlands
    Lancet 363:2139-41. 2004
    ..The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection...
  42. ncbi request reprint Challenges in the search for an HIV vaccine
    Angelique A C Lemckert
    Crucell Holland BV, 2301 CA Leiden, The Netherlands
    Eur J Epidemiol 19:513-6. 2004
    ..An immunogen that elicits broadly reactive neutralizing antibodies, however, has yet to be developed...
  43. ncbi request reprint C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia
    Alexander B H Bakker
    Crucell Holland B V, Leiden, The Netherlands
    Cancer Res 64:8443-50. 2004
    ..The AML reactivity combined with the restricted expression on normal cells identifies CLL-1 as a novel potential target for AML treatment...
  44. pmc Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
    Mieke C Sprangers
    Vaccine R and D Division, Crucell Holland BV, 2301 CA Leiden, The Netherlands
    J Clin Microbiol 41:5046-52. 2003
    ..Based on simplicity, speed, high throughput, sensitivity, and robustness, we propose a qualified assay in which Ad neutralization is monitored by luciferase reporter gene expression...
  45. pmc Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:6829-37. 2008
    ..These studies also suggest that rAd vectors warrant further assessment as candidate subunit smallpox vaccines...
  46. doi request reprint Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice
    Joseph P Shott
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Vaccine 26:2818-23. 2008
    ..Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation...
  47. pmc Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:4844-52. 2008
    ..Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens...
  48. doi request reprint EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
    Pierre Alexandre Bart
    Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Vaccine 26:3153-61. 2008
    ..Half of the 10 assessed responded in the ELISpot assay under stringent criteria, which informed the sample size for a DNA-NYVAC-C comparison to NYVAC-C alone...
  49. pmc Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors
    Shawn M Sumida
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 78:2666-73. 2004
    ..Novel adenovirus vectors that are currently being developed to circumvent the problem of preexisting anti-Ad5 immunity should therefore be designed to evade both humoral and cellular Ad5-specific immune responses...
  50. ncbi request reprint Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 8:43-50. 2003
    ..To evaluate CD4 cell count-driven strategies for the initiation of highly active antiretroviral therapy (HAART) in terms of the reduction of the incidence of AIDS-defining events in resource-poor settings...
  51. ncbi request reprint Prediction of residual time to AIDS and death based on markers and cofactors
    Ronald B Geskus
    Municipal Health Service, Cluster of Infectious Diseases, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 32:514-21. 2003
    ..In summary, for prognosis, the markers CD4 count, HIV-1 RNA load, and HIV-1 phenotype (at a high CD4 count) are equally important, and the genetic cofactors considered are of no use...
  52. ncbi request reprint Primary HIV-1 subtype C infection in Ethiopia
    Tobias F Rinke de Wit
    Ethio Netherlands AIDS Research Project ENARP at the Ethiopian Health and Nutrition Research Institute EHNRI, Addis Ababa, Ethiopia
    J Acquir Immune Defic Syndr 30:463-70. 2002
    ..One subject demonstrated a window period of at least 204 days, combined with a high preseroconversion viral load and no decline of CD4 T cells over a follow-up period of at least 3 years...
  53. ncbi request reprint AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination
    Marijn van Ballegooijen
    Institute for Biodiversity and Ecosystem Dynamics, Faculty of Science, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 34:214-20. 2003
    ..The number of long-term survivors is substantially increased only when vaccination is initiated early in an AIDS epidemic, however...
  54. ncbi request reprint Risk factors for human herpesvirus 8 infection in a cohort of drug users in the Netherlands, 1985-1996
    Neil Renwick
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Infect Dis 185:1808-12. 2002
    ..Unlike HIV-1, HBV, or HCV infection, HHV-8 infection is uncommon in Amsterdam drug users, as is HHV-8 transmission through IDU...
  55. pmc Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants
    Alexander B H Bakker
    Crucell Holland B V, Archimedesweg 4, P O Box 2048, 2301 CA Leiden, The Netherlands
    J Virol 79:9062-8. 2005
    ..In vitro exposure of RV to the combination of CR57 and CR4098 yielded no escape mutants. In conclusion, a novel combination of human MAbs was discovered suitable to replace RIG...
  56. ncbi request reprint Viral replication under combination antiretroviral therapy: a comparison of four different regimens
    Azra C Ghani
    Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK
    J Acquir Immune Defic Syndr 30:167-76. 2002
    ..04; 95% CI, 1.0-1.07). Measurement of viral load after approximately 7 days provided the most accurate measure of the degree of viral suppression induced by a given drug regimen...
  57. pmc Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 181:4188-98. 2008
    ..Thus, i.m. vaccination can overcome immune compartmentalization and generate robust mucosal CD8(+) T lymphocyte memory. These data demonstrate that the systemic and mucosal immune systems are highly coordinated following vaccination...
  58. ncbi request reprint Meeting the immense need for HAART in resource-poor settings
    Johannes A Bogaards
    Departments of Human Retrovirology, Clinical Epidemiology and Biostatistics, University of Amsterdam, Amsterdam, The Netherlands
    J Antimicrob Chemother 52:743-6. 2003
  59. pmc Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual
    Mark J Geels
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Virol 77:12430-40. 2003
    ..These results demonstrate the sequential accumulation of CTL escape in a patient during disease progression, indicating that multiple combinations of T-cell epitopes are required to control viremia...
  60. ncbi request reprint A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry
    Cecilia A W Geuijen
    Crucell Holland B V, P O Box 2048, 2301 CA Leiden, The Netherlands
    Eur J Cancer 41:178-87. 2005
    ..These experiments demonstrate that phage antibody selection in combination with affinity chromatography and mass spectrometry can be exploited successfully to identify novel antibody target molecules on malignant cells...
  61. ncbi request reprint Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
    Shawn M Sumida
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 174:7179-85. 2005
    ..These studies suggest a potential strategy for engineering novel Ad5 vectors to evade dominant Ad5-specific NAbs...
  62. ncbi request reprint Retrospective, longitudinal analysis of serum human herpesvirus-8 viral DNA load in AIDS-related Kaposi's sarcoma patients before and after diagnosis
    Abeltje M Polstra
    Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands
    J Med Virol 74:390-6. 2004
    ..Longitudinal serum samples from 19 AIDS-Kaposi's sarcoma patients, ranging from 2 years before KS till 2 years after KS diagnosis were tested. No correlation was found between viral load and progression to KS, or disease stage...
  63. ncbi request reprint Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery
    Cecilia A W Geuijen
    Crucell Holland B V, P O Box 2048, Leiden 2301 CA, The Netherlands
    J Immunol Methods 302:68-77. 2005
    ..Finally, we show that a low-affinity antibody may only detect high expression levels of a surface marker while failing to detect lower expression levels of this molecule, which may lead to a false interpretation of antibody specificity...
  64. ncbi request reprint CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals
    Mark J Geels
    Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, The Netherlands
    Virology 345:209-19. 2006
    ..This suggests that loss of T-cell reactivity may not be directly linked to HIV-specific CD4(+) T-cell responses but that increased viremia after CTL escape may influence CD4(+) T-helper responses...
  65. pmc Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys
    Anjali Nanda
    Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    J Virol 79:14161-8. 2005
    ..Moreover, these studies demonstrate that capsid chimeric rAd vectors can be constructed to combine beneficial immunologic and serologic properties of different Ad serotypes...
  66. ncbi request reprint Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia
    Jaap Goudsmit
    Department of Human Retrovirology, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 16:791-3. 2002
  67. ncbi request reprint Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
    Diane M Roberts
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 441:239-43. 2006
    ..Such chimaeric viral vectors may have important practical implications for vaccination and gene therapy...
  68. pmc Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
    ..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine...
  69. ncbi request reprint Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  70. pmc Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals
    Georgios Pollakis
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1066 CX Amsterdam, The Netherlands
    J Virol 78:2841-52. 2004
    ..These results indicate that even though R5 subtype C viruses are restrictive for virus replication, the R5-to-X4 phenotype switch can occur and does so in a manner similar to that of subtype B viruses...
  71. pmc Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity
    Anna R Thorner
    Research East Room 213, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 80:12009-16. 2006
    ....
  72. pmc Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden
    Workenesh Ayele
    Ethio Netherlands AIDS Research Project, Addis Ababa, Ethiopia
    J Clin Microbiol 45:891-6. 2007
    ..Measuring the HIV-1 burden from whole blood dried on filter paper provides a suitable alternative for low-technology settings with limited access to refrigeration, as can be found in sub-Saharan Africa...
  73. pmc Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone
    V Ann Stewart
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, USA
    Infect Immun 75:2283-90. 2007
    ..The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against P. falciparum infection in humans...
  74. pmc Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
    Peter Abbink
    Research East Room 213, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 81:4654-63. 2007
    ..These studies substantially expand the portfolio of rare serotype rAd vectors that may prove useful as vaccine vectors for the developing world...
  75. ncbi request reprint The rate of epidemiological and virological changes during the transition from nascent to concentrated HIV epidemic stage in the former Soviet Union countries
    Alexey A Nabatov
    Department of Molecular Cellular Biology and Immunology, VU Medical Center, Free University Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 23:183-92. 2007
    ....
  76. ncbi request reprint Recombination of HIV type 1C (C'/C") in Ethiopia: possible link of EthHIV-1C' to subtype C sequences from the high-prevalence epidemics in India and Southern Africa
    Georgios Pollakis
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 19:999-1008. 2003
    ..The possibility that viruses with a C' envelope have a biological advantage over the viruses with a C" envelope should be further investigated in biological and epidemiological studies...
  77. ncbi request reprint Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
    D Gray Heppner
    Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Vaccine 23:2243-50. 2005
    ..Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine...

Research Grants1

  1. CORE--VECTOR
    Jaap Goudsmit; Fiscal Year: 2005
    ..To coordinate preclinical toxicology studies under GLP conditions and prepare IND applications to support the initiation of phase I and phase II clinical trials...